tiprankstipranks
Trending News
More News >
Organon (OGN)
NYSE:OGN
Advertisement

Organon (OGN) AI Stock Analysis

Compare
1,049 Followers

Top Page

OGN

Organon

(NYSE:OGN)

Rating:51Neutral
Price Target:
$9.50
▲(4.74% Upside)
Organon's overall stock score is primarily impacted by its financial challenges, including high leverage and declining revenue. However, the stock's low valuation and positive corporate event regarding HADLIMA provide some upside potential. Technical indicators suggest a bearish trend, while the earnings call highlighted both strengths in EBITDA and challenges in revenue.
Positive Factors
Debt Management
Organon & Co. plans to delever quickly by reallocating approximately $200 million per year from its dividend cut towards debt repayment.
Revenue Growth
Organon & Co. expects low- to mid-single digit revenue growth post-2025, indicating a stable outlook for future earnings.
Negative Factors
Dividend Reduction
Organon plans to cut its dividend by 90%, ending a nearly 2-year investor debate, which might concern income-focused investors.
Financial Health
Updated financials include a $6 million charge reported in the first quarter, which could impact the company's financial health.
Market Position
The stock is positioned as a low growth story with an LOE overhang, suggesting limited potential for significant valuation increases.

Organon (OGN) vs. SPDR S&P 500 ETF (SPY)

Organon Business Overview & Revenue Model

Company DescriptionOrganon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.
How the Company Makes MoneyOrganon makes money through the sale of its healthcare products and solutions across its three main business segments. In Women's Health, revenue is generated from contraceptives, fertility solutions, and hormone therapies. The Biosimilars segment contributes to earnings through the development and commercialization of biologic medicines that are highly similar to already approved reference products, offering cost-effective alternatives. The Established Brands segment, which consists of a wide range of legacy pharmaceutical products, provides a stable revenue stream as these products continue to be used in various therapeutic areas. Additionally, Organon engages in strategic partnerships and collaborations to enhance its product offerings and expand market reach, further contributing to its revenue.

Organon Earnings Call Summary

Earnings Call Date:Aug 05, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Oct 30, 2025
Earnings Call Sentiment Neutral
The earnings call reflected a mixed performance for Organon. While there were strong achievements in adjusted EBITDA and biosimilars growth, challenges such as the decline in U.S. Nexplanon sales and the revenue impact from loss of exclusivity in the EU were notable. The decision to discontinue the endometriosis program was another setback. Overall, the company's financial discipline and strategic debt repayment were positives against a backdrop of operational challenges.
Q2-2025 Updates
Positive Updates
Strong Adjusted EBITDA Performance
Adjusted EBITDA for the quarter was $522 million, representing a 32.7% margin. Year-to-date, adjusted EBITDA is $1 billion with a 32.4% margin.
Debt Repayment
Organon repaid approximately $350 million of principal on long-term debt in the second quarter, aiming to achieve net leverage below 4x by year-end.
Growth in Women's Health and Biosimilars
The Women's Health franchise grew 2% at constant currency, with the fertility business up 15%. Biosimilars, led by Hadlima, grew 68% compared to the prior year.
Vtama Performance
Vtama revenue reached $31 million, up 35% sequentially and 70% year-over-year, adding over 20,000 new prescribers since launch.
Negative Updates
Revenue Decline
Total revenue for the quarter was $1.6 billion, down 1% at constant currency, impacted by the loss of exclusivity of Atozet in the EU.
Nexplanon U.S. Decline
Nexplanon sales declined by 5% in the U.S. due to constrained funding for contraceptive products, though it grew 10% outside the U.S.
Endometriosis Program Discontinuation
Organon failed to see efficacy in the 6219 endometriosis study, leading to the discontinuation of this and the backup molecule program.
Company Guidance
During the second quarter of 2025, Organon reported revenue of $1.6 billion, which represented a 1% decrease at constant currency. Despite this decline, the company raised its full-year revenue guidance by $100 million at the midpoint, influenced by favorable foreign exchange movements. Adjusted EBITDA for the quarter stood at $522 million, marking a 32.7% margin, with year-to-date adjusted EBITDA reaching $1 billion or a 32.4% margin. Organon reaffirmed its adjusted EBITDA margin guidance range of 31% to 32% and projected over $900 million in free cash flow for the year. The Women's Health franchise saw a 2% growth at constant currency, driven by a 15% rise in the fertility business and double-digit growth from Jada. Nexplanon experienced a 1% decline in constant currency, with a 5% decrease in the U.S. but a 10% increase outside the U.S. The biosimilars segment outperformed expectations, with Hadlima contributing significantly, almost reaching $100 million in revenue by June, up 68% year-over-year. Vtama revenue reached $31 million for the quarter, showing a 35% sequential increase and a 70% rise compared to the previous year. Organon also repaid approximately $350 million of principal on long-term debt, aiming to achieve a net leverage ratio below 4x by year-end, with a long-term target of 3.5x or below by the end of 2026.

Organon Financial Statement Overview

Summary
Organon is facing financial challenges with declining revenue and profitability, high leverage, and reduced cash flow generation. The company needs to address its high debt levels and improve operational efficiency to stabilize its financial position.
Income Statement
45
Neutral
Organon's income statement shows a significant decline in revenue with a TTM revenue growth rate of -25.51%. Gross profit margin is relatively stable at 57.18%, but net profit margin has decreased to 11.92%. EBIT and EBITDA margins have also declined, indicating reduced operational efficiency. The company faces challenges in maintaining revenue and profitability.
Balance Sheet
30
Negative
The balance sheet reveals a high debt-to-equity ratio of 16.52, indicating significant leverage. Return on equity is low at 1.82%, reflecting limited profitability relative to shareholder equity. The equity ratio is weak, suggesting potential financial instability. The company needs to address its high leverage to improve financial health.
Cash Flow
40
Negative
Cash flow analysis shows a decline in free cash flow growth by -44.84% TTM, indicating reduced cash generation. The operating cash flow to net income ratio is 0.36, suggesting moderate cash conversion efficiency. The free cash flow to net income ratio is 0.62, which is decent but declining. The company needs to enhance its cash flow management.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue6.28B6.40B6.26B6.17B6.30B8.10B
Gross Profit3.53B3.71B3.75B3.88B3.92B4.75B
EBITDA1.52B1.61B1.44B1.69B1.81B2.99B
Net Income700.00M864.00M1.02B917.00M1.35B2.16B
Balance Sheet
Total Assets13.50B13.10B12.06B10.96B10.68B10.43B
Cash, Cash Equivalents and Short-Term Investments599.00M675.00M693.00M706.00M737.00M500.00M
Total Debt8.90B8.88B8.76B8.91B9.13B31.00M
Total Liabilities12.77B12.63B12.13B11.85B12.19B11.25B
Stockholders Equity733.00M472.00M-70.00M-892.00M-1.51B-820.00M
Cash Flow
Free Cash Flow323.22M588.00M538.00M431.00M1.97B1.91B
Operating Cash Flow531.29M939.00M799.00M858.00M2.46B2.19B
Investing Cash Flow-371.21M-513.00M-260.00M-420.00M-481.00M-258.00M
Financing Cash Flow-160.30M-368.00M-569.00M-433.00M-1.33B-2.17B

Organon Technical Analysis

Technical Analysis Sentiment
Negative
Last Price9.07
Price Trends
50DMA
9.63
Negative
100DMA
9.91
Negative
200DMA
12.47
Negative
Market Momentum
MACD
-0.12
Negative
RSI
43.22
Neutral
STOCH
30.96
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OGN, the sentiment is Negative. The current price of 9.07 is below the 20-day moving average (MA) of 9.27, below the 50-day MA of 9.63, and below the 200-day MA of 12.47, indicating a bearish trend. The MACD of -0.12 indicates Negative momentum. The RSI at 43.22 is Neutral, neither overbought nor oversold. The STOCH value of 30.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OGN.

Organon Risk Analysis

Organon disclosed 44 risk factors in its most recent earnings report. Organon reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Organon Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
82
Outperform
$142.93B13.7612.16%6.86%14.72%
78
Outperform
$79.75B18.2523.04%4.13%3.46%-13.29%
76
Outperform
$122.44B12.778.39%4.40%-9.32%120.62%
71
Outperform
$8.58B20.485.41%1.45%10.05%98.22%
68
Neutral
$95.95B19.3429.31%5.21%2.57%
51
Neutral
$7.83B-0.15-40.10%2.29%21.46%-2.01%
51
Neutral
$2.36B3.50159.64%6.62%-1.02%-30.57%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
OGN
Organon
9.07
-12.36
-57.68%
BMY
Bristol-Myers Squibb
47.21
-0.27
-0.57%
GSK
GlaxoSmithKline
39.83
-2.03
-4.85%
GRFS
Grifols SA
9.84
0.86
9.58%
PFE
Pfizer
24.92
-1.92
-7.15%
SNY
Sanofi
50.30
-4.29
-7.86%

Organon Corporate Events

Business Operations and StrategyFinancial Disclosures
Organon Reports Q2 2025 Financial Results and Guidance
Neutral
Aug 5, 2025

Organon reported its financial results for the second quarter of 2025, with a revenue of $1.594 billion, a slight decrease from the previous year. The company achieved a net income of $145 million and repaid $345 million of long-term debt, aiming for a net debt to Adjusted EBITDA ratio of less than 4.0x by year-end. Organon raised its full-year revenue guidance to between $6.275 billion and $6.375 billion, while maintaining its Adjusted EBITDA margin guidance. The quarter saw growth in women’s health and biosimilars, offset by declines in established brands due to the loss of exclusivity in key markets.

Executive/Board ChangesShareholder Meetings
Organon Concludes Annual Meeting with Key Decisions
Neutral
Jun 12, 2025

On June 10, 2025, Organon held its Annual Meeting where stockholders voted on five proposals. The meeting saw approximately 83% of shares represented, with key decisions including the election of eleven directors, approval of executive compensation, amendment of the 2021 Incentive Stock Plan, ratification of PricewaterhouseCoopers LLP as the accounting firm, and rejection of a stockholder proposal for a new Director Election Resignation Guideline.

Product-Related AnnouncementsRegulatory Filings and Compliance
Organon Receives FDA Interchangeability for HADLIMA
Positive
May 27, 2025

On May 27, 2025, Organon & Co. announced that the U.S. Food and Drug Administration (FDA) granted interchangeability designation to their product HADLIMA™ (adalimumab-bwwd) as a biosimilar to Humira®. This designation allows pharmacists to substitute HADLIMA for Humira without consulting prescribers, potentially increasing patient access and reducing costs. The designation is based on studies demonstrating comparable pharmacokinetics, efficacy, safety, and immunogenicity with Humira. Organon emphasizes that this approval could lead to significant savings for patients and the healthcare system.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 19, 2025